Quest Diagnostics (DGX) Tops Q2 EPS by 5c; Maintains FY Adjusted EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies Raises Price Target on Quest Diagnostics (DGX) to $86 Following 2Q Earnings Report
July 22, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Quest Diagnostics (NYSE: DGX), and raised the price target to $86.00 (from $75.00), following the company's 2Q earnings report. DGX posted its 3rd consecutive quarter of positive organic volume growth. However, pricing remains under pressure.
Analyst Brian Tanquilut... More
Quest Diagnostics (DGX) PT, Estimates Raised at Evercore ISI Amid Solid Q2
July 21, 2016 12:00 PM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Quest Diagnostics (NYSE: DGX) to $89.50 (from $78.50) but maintained a Hold rating following results.
The firm raised FY 2016 EPS from $5.10 to $5.15, FY 2017 EPS from $5.55 to $5.60 and FY 2018 EPS from $5.95 to $6.15.
Muken commented, "Quests turnaround momentum continues as volumes have stabilized in the LSD, with a consistent price headwind... More
